deucravacitinib hydrochloride

PF-303 is a covalent-reversible BTK inhibitor. Inhibitors of Bruton's tyrosine kinase (BTK) possess much promise for the treatment of oncologic and autoimmune indications.

Deucravacitinib hydrochloride is a Highly Potent and Selective Allosteric Inhibitor of TYK2. BMS-986165 Blocks Il-12,IL-23 and type I Interferon Signaling and Provides for Robust Efficacy in Preclinical Models of Inflammatory Bowel Disease. MS-986165 potently binds to the Tyk2 pseudokinase domain (Ki = 0.02 nM),and is highly selective against a panel of 265 kinases and pseudokinases. The compound potently inhibited IL-23-,IL-12-,and Type I interferon-driven cellular signaling and transcriptional responses (IC50 range 2-14 nM).